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Abstract 
Diabetes related foot disease remains a common problem. For wounds, classic 
teaching recommends the treatment of any infection, offloading the wound and 
ensuring a good blood supply, as well as ensuring the other modifiable risk factors 
are addressed and optimised. There remain, however, several questions about these 
and other aspects of the care for diabetes related foot disease.  
 
Some of these questions are addressed in this report. In particular, the impact of 
newer technologies in the identification of any organisms present in a wound, as well 
as the use of novel approaches to treat infections. The use of new technology in 
identifying people at risk of developing foot ulceration using remote sensing is also 
considered, in an attempt to allow early intervention and prevention of foot ulcers.  
 
The psychological impact of foot disease is an often overlooked, but with an 
increasing number of publications on the subject the role that psychology plays on 
foot disease such as ulcers and Charcot neuroarthropathy – as cause and effect - is 
considered. Finally, because of the heterogeneity in diabetic foot studies, this makes 
comparing results difficult. A recently published document for ensuring a 
standardised way of reporting foot disease trials is discussed.   
Novelty statement 
Foot disease is relatively common in people with diabetes. Newer technologies for 
the management of wound infections are on the horizon 
 
Remote sensing technologies are being developed to allow identification of at risk 
tissues at an early stage, allowing for intervention and prevention of foot wounds 
 
The psychological impact of foot disease is often under-appreciated but has a 
potentially significant on cause and effect on ulcers and Charcot neuroarthopathy 
 
Comparing outcomes of published trials in foot disease has been difficult because of 
the lack of standardisation. A framework for reporting standards has recently been 
published to help overcome this  
Introduction 
Incident and prevalent diabetes related foot disease remains common [1,2]. People 
with diabetes have a 25% chance of developing a foot ulcer in their lifetime [3], and it 
has been estimated that approximately 2.5% of the 415 million adults worldwide who 
have diabetes also have diabetic foot ulcers [4]. This translates to approximately 
86,000 people in the UK having diabetic foot ulcers at any given time. The 
combination of neuropathy, with or without peripheral vascular disease, increases 
the risk of ulceration, and subsequent infection. Around a quarter of all diabetes 
related hospital admissions within Europe and the USA stem from diabetic foot 
infections [5]. As a result, up to 85% of lower extremity amputations are preceded by 
ulcers, most of which were infected by difficult-to-treat polymicrobial communities. In 
the UK, diabetes related foot disease accounts for approximately £1 in every £150 
spent in the National Health Service [1].  
 
For many years, it has been standard practice to treat diabetic foot ulcers with a 
combination of any of the following:  
 appropriate wound dressing  
 offloading 
 antibiotics 
 improving the blood supply 
However, what the best way of offloading the foot is uncertain. In addition, whilst 
there are widely respected guidelines available on treating infection [6], the choice of 
antibiotics is also hotly debated, and relies on local sensitivities, the availability of 
antimicrobial agents and frequently, local microbiologist preferences. 
Revascularisation is dependent on local availability; non-invasive techniques such as 
angioplasty are often only available in specialist centres, meaning that many units in 
low resource environments do not have access to this procedure, let alone a 
vascular surgeon. Even after effective treatment, relapse probability is ~70% [7] 
which frequently leads to amputation.  
 
On this background, newer aspects of the care and management of the diabetic foot 
are emerging. Martha Clokie and Alice Greenway discuss the impact of newer 
technologies in the identification of the organisms present in an ulcer, as well as 
novel approaches to treat infections. Keith Harding and Nia Jones also discuss 
newer technologies, in particular various uses of remote sensing, that may help in 
the early detection of tissue damage, thus allowing more timely intervention to 
prevent ulceration developing.  
 
Recent data suggest that only a small proportion of diabetes related research 
funding goes into psychosocial studies [8]. This is despite the psychological burden 
of people with foot disease being larger than in the population without diabetes, or in 
those with diabetes, but without diabetic foot ulcers. Kavita Vedhara discusses the 
relationship between the psychological aspects of foot disease, and its relationship 
to cause or effect of the condition.  
 
Despite the increasing prevalence, diabetes related foot disease research has 
received little investment over recent years  [9]. As a result, many studies have been 
of relatively poor quality with a great deal of heterogeneity, even when addressing 
the same issues, making direct comparison between studies difficult. Fran Game 
discusses her recent commentary which outlines a set of reporting standards for foot 
related research [10].   
New Horizons in Understanding the Microbiology of Foot Disease 
 
Diabetic foot ulcers need to be treated with effective antimicrobials. As with many 
chronic diseases, persistent antibiotic treatment often fails because wounds are 
colonised by antibiotic-resistant bacteria, or because resistance in situ is selected for 
during treatment. Identifying the causative agents and selecting effective 
antimicrobials would improve patient treatment. The purpose of this section is to 
highlight 1) the composition of foot ulcer polymicrobial bacterial communities, 2) 
current diabetic foot ulcer diagnosis, 3) culture independent methods to characterise 
infection and 4) novel antimicrobials that could be effectively exploited.  
 
Microbiology and current diagnosis of diabetic foot ulcers 
Effective diabetic foot infection treatment requires an understanding of the formation 
and composition of the diabetic foot ulcer microbiota (bacteria associated with 
infection). Our knowledge of this is largely based on culture-based studies that have 
revealed that bacterial colonization evolves from precursor bacteria into complex 
polymicrobial communities. Ulcer duration and depth are positively correlated with 
microbial diversity and are associated with specific pathogens [11] Figure 1 shows 
how species number and composition change with disease state and severity [12].  
In brief foot ulcers are associated with a complex polymicrobial community, in which 
Staphylcoccus aureus is a dominant early coloniser of wounds together with 
Enterococcus spp, Corynebacterium spp and coagulase-negative staphylococci. 
These species are then followed in succession by Pseudomonas and various 
members of the Enterobacteriacea, followed by a set of strict anaerobes during 
severe infection.  
 Sampling and diagnosis of bacteria  
The diagnosis of most diabetic foot ulcers is based on the presence of clinical signs 
and symptoms [13]. Most frequently, tissue biopsy and ulcer fluid aspirates are sent 
for culture-based identification [14]. Less invasive swabbing from the base of the 
ulcer is also used to detect surface associated bacteria but does not detect bacteria 
associated with deeper structures [15].  
 
Insights from 16S ‘bar coding’ 
The use of non-culture based molecular microbiological techniques to characterise 
foot infection microbiota could significantly enhance our understanding of the 
composition and abundance of the infection and guide effective antimicrobial 
selection. These techniques have the advantage over culture-based approaches 
because they are not dependent on the culturability of the bacteria. This is 
particularly pertinent for diabetic foot ulcers, which are typically colonised by 
anaerobes that are notoriously difficult to isolate. The most commonly used culture-
independent approach is to extract total DNA from the whole bacterial community 
and use universal Polymerase Chain Reaction primers to amplify and sequence the 
16S RNA gene. After further analysis (‘deep sequencing’), the sequence data are 
then compared to reference databases to establish the type and diversity of species 
[16]. Because all bacteria encode ribosomes, the use of 16S ribosomal RNA as a 
‘bar-code’ has revolutionised our ability to describe bacterial communities and is now 
well established in environmental and medical microbiology, and recently provided 
fascinating insights into the bacteria associated with diabetic foot ulcers [17]. 
 
16S ribosomal RNA analysis has shown that chronic infections possess a far wider 
array of micro-organisms than was identified from standard culture-based 
approaches [11]. This raises concerns about the use of culture as a diagnostic tool in 
a clinical setting. Even though 16S sequencing is limited to the detection of bacteria; 
the approach could be modified to unravel the contributions from protozoa, virus and 
fungi.  
Although 16S sequencing gives a powerful resolution on the components and 
structure of the DFU microbiota, it does not provide mechanistic information on 
bacterial physiology or other useful traits such as antibiotic resistance profiling. This 
requires full metagenomic analysis techniques from whole genome sequencing or 
potentially transcriptome profiling to see which genes are expressed and when. In 
addition, antibiotic resistance targeting could also be carried out by amplifying known 
genes that encode for the ‘resistome’ (all known genes that encode for antibiotic 
resistance). 
 
Problems associated with antibiotic resistance and antibiotic penetration  
Multi-drug resistant bacteria (superbugs) are becoming a major health concern; 
treatment can be difficult, expensive and sometimes impossible to cure. The 
exponential rise in antibiotic resistant bacteria has negatively impacted diabetic foot 
ulcer treatment strategy. One of the key factors that promotes antibiotic resistance is 
wound chronicity [18]. Unfortunately, most patients undergo extensive drawn out 
wound care treatment, with intermittent periods of antibiotic treatment, aimed at the 
putative causative agent. These essentially prophylactic treatments can lead to 
infection within previously unaffected ulcers. Furthermore, without proper diagnosis 
of the infection with deep tissue swabs, selection of the wrong antibiotic can lead to 
chronic ‘superbug’ infections [19].  
 
Bacteriophages 
One of the key problems associated with diabetes is peripheral vascular disease and 
wound ischaemia [20]. Poor antibiotic penetration into tissues because of a lack of 
blood flow is another reason why antibiotics are so unsuccessful. Both the lack of 
effective penetration of antibiotics, and problems with antibiotic resistance mean that 
novel approaches to treat infection are needed. One promising alternative to 
standard antibiotics is the use of bacteriophages, or phages, which are viruses that 
target and kill bacteria. 
 
The use of bacteriophages is justifiable when one considers that, as with all bacterial 
systems, they are already a natural component of the diabetic foot ulcer microbiota. 
However, by altering the balance and composition of viruses present they could be 
used to manipulate the bacterial part of the microbiota and remove conditions that 
facilitate disease progression. Unlike conventional antibiotics, these phages have 
several traits that can overcome difficulties associated with resistance and 
penetration, and thus could be useful to remove or reduce the bacteria associated 
with infection.  
 
Bacteriophages and foot ulcers 
Phages have a long history of use in Georgia, Russia, Poland and France but fell out 
of favour after the discovery of antibiotics. Their use as a therapy, however, is 
undergoing a resurgence of interest in the western world due to: 1) their exquisite 
specificity; 2) their ability to self-replicate and therefore ‘auto dose’ in situ to clear 
infection, 3) and their ability to penetrate biofilms. They can be used as an 
alternative, or an adjunct to conventional antibiotics. Phages have access to two 
main life cycles, one where they integrate and reside within bacterial cells and a 
second where they infect and kill the bacteria. It is those phages that access this 
secondary lytic cycle that are suitable for therapeutic use. In contrast to when 
bacteriophages were first isolated we now have a vast array of tools such as 
genome sequencing and advance proteomics and a much better understanding of 
bacteria-phage relationships, that can be utilised to inform their successful 
development. 
 
Phages that target S. aureus and Pseudomonas spp 
Because complex polymicrobial communities are associated with foot ulcers, 
conceptually a phage mixture could be developed that targets and removes each 
bacterial pathogen. Alternatively a mixture could be developed that removes one or a 
few key bacterial members to prevent further bacterial colonisation, and thus ‘reset’ 
the microbial succession associated with disease. Either approach relies on a better 
understanding of the foot ulcer microbiota, which could come from 16S profiling 
described above, or personalised phage therapy (testing diabetic foot infection 
samples for susceptibility to different phages and selection of the most effective). An 
obvious place to start in terms of removing bacteria is by using S. aureus phages 
because this pathogen is the dominant early coloniser (Figure 1) [11]. Treatment of 
S. aureus could prevent colonisation and thus chronic infection. A beneficial property 
of anti-Staphylococcus phages is their relatively broad host range, which means that 
only 2-3 phages are needed to target and kill the most representative S. aureus 
strains. In contrast, in Gram-negative infections relatively high phage numbers (>10) 
are often required to target the causative agent [21].  
 
Current usage, safety and efficacy trials of S. aureus and Pseudomonas spp phages 
In Georgia and Russia, these phage products are available over the counter at 
pharmacies [22]. MRSA strains of S. aureus do not affect phage efficacy, and these 
strains are targeted by phages cocktails such as “Pyophage” that contains phages 
active against S. aureus, Pseudomonas spp., and Streptococcus spp [23]. This 
Pyophage formula and other phage mixtures are commonly used to treat diabetic 
foot ulcers in Georgia but in the western world phage therapy is still awaiting general 
acceptance. To ensure that phages are used effectively and sustainably in the UK, 
investigation of well-characterised bacteriophage sets with optimal host-ranges and 
physiological properties is needed, in the context of current practices and regulation. 
This research has not received adequate funding and thus has largely not been 
performed. There needs to be a closer connection between microbiologists and 
clinical practitioners, to develop products and ultimately collect clinical trial data. 
 
Further evidence of efficacy can be seen in Poland where S. aureus and 
Pseudomonas phages were used over many years to treat wound infections. One 
study reported the treatment of 550 people with phages between 1981-1986, 518 of 
whom had failed to respond to antibiotics. The phages targeted various bacteria 
including S. aureus and P. aeruginosa. Positive results were obtained in 92.4% of 
cases, and 6.9% demonstrated transient improvement [24].  
 
In the USA, a Phase I safety trial on phages suitable for wound infection was 
conducted in the Wound Care Centre in Lubbock, Texas [25]. The trial used a fully 
sequenced well-defined phage cocktail (WPP-201) imported from the Eliava institute 
in Georgia, containing phages against S. aureus, P. aeruginosa, and Escherishia 
coli. In this trial 39 people with chronic leg ulcerations were successfully treated 
without any observed side effects.  
 
Currently smaller phase 1 safely trials have shown success and phase 2 efficacy 
trials appear to show promise. It is hoped that these will set the groundwork for 
further large-scale work too assess the efficacy of Staphylococcal phages to treat 
diabetic foot ulcers. However, to test Staphylococcus phages in larger scale clinical 
trials and determine the impact of adding phages that target the other pathogens 
would require some fundamental research because many pathogens involved in foot 
infections do not have well characterised phages. There also needs to be a greater 
synergy between microbiologists and foot specialists.  
 
Remote Sensing in the Assessment of Diabetic Foot Disease 
It is generally accepted that early diagnosis of risk factors associated with diabetic 
foot ulcers is a prerequisite for maintenance of lower limb health [26]. In comparison 
to current clinical assessment methods, the evolution of innovative technologies 
provides new opportunities for remotely detecting and monitoring diabetic 
neuropathy and angiopathy earlier in the disease progression. This section explores 
the role of remote sensing in the assessment and monitoring of diabetic foot disease. 
 
International best practice guidelines recommend that people with diabetes are 
assessed on an annual basis for peripheral neuropathy and peripheral arterial 
disease using a range of simple screening tests [27]. However, a recent systematic 
review reported that the quality of evidence demonstrating the efficacy of this 
intervention was relatively low [28]. This was attributed to a paucity of high quality 
randomised controlled trials in the screening, prevention and treatment of diabetic 
foot ulcers (discussed below).  
 
Measuring skin temperature is considered one of the most reliable indicators of 
cutaneous perfusion, and evidence suggests that infrared thermographic monitoring 
may be an effective method of predicting tissue viability complications in the diabetic 
foot [28,29]. Dermal thermography is currently used in routine clinical practice to 
detect temperature differences between the ipsilateral and contralateral foot in 
Charcot neuroarthropathy but emerging evidence suggests that this technology 
could be adopted to support self-monitoring of diabetic foot disease [28].  
 
There is a marked increase in temperature associated with tissue stress and sub-
clinical inflammation, which may develop 7 days prior to the onset of foot ulceration 
[30,31]. This suggests that performing daily foot temperatures could prevent lower 
limb threatening foot ulceration in this high risk population. However, one of the 
documented drawbacks with the use of these self-monitoring devices (TempTouch®, 
TempStat™ and Thermoscale®) is the lack of standardised reference criteria. Partly 
this is because foot temperatures are known to vary in people with diabetes due to 
the adverse effects of microangiopathy, levels of physical activity and changes in 
ambient temperature. Despite acknowledging these intrinsic and extrinsic limitations 
the literature recommends using the corresponding area on the contralateral foot as 
a reference point [30-32], and a temperature difference greater than 2.2⁰C being 
regarded as a precursor of tissue stress and sub-clinical inflammation [32].  
 
Hyperspectral imaging is currently a laboratory based assessment method used to 
determine oxygen saturation in human tissue and detect early microcirculatory 
changes in the diabetic foot [33,34]. Yudovsky et al investigated the validity of 
hyperspectral tissue oximetry imaging in predicting foot ulcer risk in people with type 
1 and type 2 diabetes [35]. They established that hyperspectral tissue oximetry had 
the ability to detect (with a sensitivity of 95% and specificity of 80%) ischaemic 
changes and inflammatory complications, on average, 58 days prior to cutaneous 
pre-ulcerative changes becoming clinically evident. Hyperspectral imaging 
technology has also been evaluated as a tool for predicting the healing potential of a 
foot ulcer with a reported sensitivity and specificity of 80% and 74%, respectively 
[36]. This technology has the potential for miniaturisation as do many other current 
laboratory based devices and as such develop greater utility in the patients’ own 
environment for monitoring and detection of foot complications. 
 
Skin perfusion pressure, in contrast to hyperspectral imaging, is a portable tool used 
in routine clinical practice to diagnose small vessel disease in high risk populations 
and assess the healing potential of chronic wounds in the lower limb. Skin perfusion 
pressure is not affected by diffuse vascular calcification and was superior in the 
diagnosis of peripheral arterial disease in people with diabetes when compared 
against ankle and toe brachial pressure indices (ABPI and TBPI) and transcutaneous 
partial pressure of oxygen (TcPO2) [37,38]. Hyperspectral tissue oximetry and skin 
perfusion pressure (Sensilase PAD-IQ®) may therefore provide opportunities for 
earlier detection of peripheral arterial disease in people with diabetes, but the one 
major drawback is that the application of these technologies is driven by the clinician 
and not the person with diabetes.  
 
The presence and severity of infection is regarded as the single greatest threat to 
lower limb survival. In routine clinical practice, features of infection are established 
following visual inspection and microbiological sampling but these methods do not 
accurately represent the overall bacterial load within the wound bed [6]. 
MolecuLightTM is a novel handheld fluorescence imaging device that identifies 
bacterial presence and distribution in and around the wound (Figure 2). This remote 
sensing device provides instant and precise detection of potentially harmful bacteria 
to guide clinicians at the point of care. A recent pilot study reported that this device 
can be used to guide wound treatment and monitor treatment response by tracking 
wound size and changes in bacterial bioburden within the wound bed [39]. Further 
high quality studies are needed to compare the clinical effectiveness of systemic 
therapy versus topical treatments to eliminate harmful bacteria but the introduction of 
autofluorescence imaging in individuals with wounds may have the potential to 
provide novel solutions in the ever increasing battle against antibiotic resistance and 
support improved antibiotic stewardship.  
 
Wearable technology is another evolving field in the monitoring and treatment of 
diabetic foot disease since sensory and motor complications associated with 
peripheral neuropathy often result in altered proprioception and ataxic gait patterns. 
Human exoskeleton robots are in early development but some of these devices have 
remote body sensors which consist of shoe-embedded force sensors and walking 
canes to aid with gait difficulties and alert people to the risk of falls when standing 
from a sitting position [40]. One simple and inexpensive method of adopting wearable 
technology into practice would be to encourage patients to wear pedometers to 
monitor their physical activity levels and visually inspect their feet daily for evidence 
of tissue trauma. This intervention would enable the person to recognise when they 
need to limit their activity levels and seek advice from their podiatrist. PulseFlowDFTM 
is an offloading device which has taken the concept of monitoring physical activity to 
another level (Figure 3). It has built-in monitoring software that enables the clinician 
to capture data on the use of the offloading device. Previous work has suggested 
that people with ulceration may be more active than they admit to their treating 
clinician [41]. 
 
The opportunities to expand on the role of remote sensing technology in patient 
centred care are limitless and this technology can play an important role in the 
assessment of diabetic foot disease despite the limitations and paucity in empirical 
evidence. Dermal thermography and hyperspectral imaging have the capacity to 
diagnose tissue viability complications associated with pressure injury and ischaemia 
earlier in the natural course of the disease whilst autofluorescence imaging may 
have the potential to change the landscape of standard care in the treatment of 
diabetic foot infections.  
 
The transition of incorporating remote sensing technology for self-monitoring diabetic 
foot disease in routine clinical practice may be challenging for both people with 
diabetes and clinicians. With the ever increasing socioeconomic burden of foot 
complications on global healthcare resources we need to find novel solutions that 
encourage this patient population to engage in their care - a theme that is continued 
in the next section. 
 
Psychological and Behavioural Aspects of Foot Disease and its Management:  
Cause versus Consequence 
 
There can be little doubt that diabetic foot disease has psychological and 
behavioural consequences. In terms of the former, and mood in particular, data 
suggest that over a third of individuals are anxious or depressed [42]. The rates of 
psychological morbidity may be even higher in people with Charcot foot [43]. Health-
related quality of life is significantly impaired in people with both healed and 
unhealed ulcers, compared with the general population and individuals with diabetes 
but no history of ulceration [44]; and perhaps not surprisingly, significant 
deteriorations in quality of life are evident in those with non-healing ulcers [45].  
 
The behavioural consequences of foot disease are far-reaching. For example, the 
International Working Group on the Diabetic Foot made a number of 
recommendations in 2016 on footwear and offloading interventions aimed at 
preventing ulceration or promoting healing [46]. With the exception of surgical 
recommendations, all of the suggested approaches require the individual to engage 
with treatments they may be unable or unwilling to tolerate. Furthermore, it is of 
interest that 9 out of 13 recommendations were based on low quality evidence, with 
only one (offloading with a non-removable device) being derived from high quality 
evidence. This juxtaposition of potentially unwelcome behavioural demands, 
advocated on the basis of a weak evidence base, leads to people reporting low 
knowledge of, and exhibiting poor adherence with, foot care behaviours [47,48]. 
 
The emotional and behavioural consequences of diabetic foot disease are evidently 
far-reaching. However, of potentially greater interest is evidence suggesting that 
these emotional and behavioural sequelae may influence clinical outcomes i.e., have 
a causal role.  
 
In terms of psychological determinants, several studies have explored the 
relationship between mood and related psychological constructs with ulcer risk, 
healing, amputation and mortality. For example, large cohort studies suggest that 
depression is associated with a two to three fold increase in incident foot ulcers 
[49,50]. In contrast, the evidence regarding depression and recurrence is less clear, 
with Gonzalez et al [51], reporting that depression predicts first ulcers, but not 
recurrence, while Monami et al reported that ulcer recurrence over 12 months was 
significantly associated with depression [52]. The evidence pertaining to ulcer 
healing appears to be equivocal. For example, depression predicted healing in the 
study by Monami et al [52]. However, in a more recent study, healing was predicted 
by coping style not depression, although depression was significantly associated 
with healing rate (as measured by change in ulcer area) accounting for over 30% of 
the variance of this outcome [53]. Finally, a number of studies have examined the 
relationship between indices of psychological functioning and mortality. Depression, 
health-related quality of life and patient beliefs regarding their ulcers, all predict 
mortality [54-56]. 
 
People with diabetes are encouraged to engage in a variety of different behaviours 
to reduce their risk of ulceration and promote healing, although the underlying for 
these behaviours is unclear. One behaviour often shrouded in uncertainty is physical 
activity. This is largely because its merits or otherwise vary according to the nature of 
the activity and the ulcer status. For example, several studies have shown that, in 
those at risk of ulceration but who are ulcer free, moderate and regular physical 
activity may be protective [57,58]. In contrast, during active ulceration, weight 
bearing activity can be detrimental and consequently minimal or non-weight bearing 
activity is recommended [59]. Other common behaviours include the use of 
prescribed footwear and monitoring foot temperature. The evidence base for these 
behaviours in primary prevention is unclear because, as a recent review has 
suggested (discussed in the next section), only a few low quality studies have been 
published [28]. In contrast, trial evidence provides stronger support for these 
behaviours influencing ulcer recurrence [28]. But perhaps of greater import is the 
observation by Bus et al [60] that, for behaviours with a stronger evidence base, it is 
clear that adherence is critical. They note that in all trials that have examined 
adherence, non-adherent individuals have significantly poorer outcomes and that the 
size of the ‘adherence effect’ is large ranging from 58-98%. 
 
It is clear that more trial evidence is needed to address the areas of uncertainty, 
such as whether the effects of psychological and behavioural determinants are 
independent [51] and whether and why effects might vary between related clinical 
outcomes [53]. Notwithstanding these issues, it is clear that psychological and 
behavioural factors influence ulcer outcomes. However, paradoxically, patient-
focussed interventions in the diabetic foot focus not on psychological and 
behavioural factors, but overwhelmingly on education. This is despite the fact that 
successive systematic reviews have not found that education improves clinical 
outcomes [61-65]. Even the small number of complex interventions that have been 
trialled to date (n=6) have neglected psychological and behavioural factors. Instead 
they too have focussed predominantly on patient and/or health care professional 
education, combined with changes in health care structure or organisation; and 
again have failed to show effects on clinical outcomes [66]. 
 
The prevention and management of diabetic foot ulcers is a complex problem that 
requires complex solutions. But it is time, as recommended by NICE, for these 
complex solutions to target psychological and behavioural factors with a view to 
achieving effective and cost-effective improvements in clinical outcomes [67]. 
 
Diabetic Foot Disease: Assessing the Strengths and Weaknesses of Reported 
Studies 
 
High quality evidence to support clinicians in providing best practice treatments for 
both the prevention and management of foot disease is sadly lacking. Repeated 
systematic reviews on the subject by the International Working Group of the Diabetic 
Foot have drawn attention to the paucity of quality research and the urgent need for 
more high quality studies in this field [28,68-72]. 
 
There is no shortage of general guidance available on the general principles of trial 
design and conduct (e.g. a CONSORT statement for randomised trials [73], 
STROBE for epidemiological studies [74], and PRISMA for systemic reviews/meta-
analyses [75]). Systems already also exist for scoring studies of different design [76] 
for example the GRADE system [77].  
 
Hitherto, it may have been considered unnecessary to produce any further guidance 
on the design and conduct of studies specifically to examine aspects of diabetic foot 
disease, but it is now evident that the complexity of the clinical area including the 
number of diverse and overlapping processes involved in the development and 
presentation of foot ulcers – as well as their effect on healing – requires a more 
standardised approach. For example, there are number bedside tests available to 
clinicians to describe vascular disease [69], but as the majority presenting with 
diabetes and foot disease will also have peripheral neuropathy these tests may be 
adversely affected, and the clinician misled as to the scale of vascular disease 
present unless all the patient clinical details are described. Additionally, the failure to 
address neuropathy by providing suitable offloading during a study of diabetes and 
vascular disease - particularly one which involves wound healing - could also 
undermine any conclusions drawn.  
 
Recently a subgroup of the International Working Group of the Diabetic Foot 
published guidelines on the standards of reporting of studies on the diabetic foot and 
lays out some fundamental items to be considered when either setting up or 
assessing a study in either the prevention or management of the diabetic foot 
disease [10]. 
 
Whilst the details will vary between studies of ulcer prevention and studies of ulcer 
management and between different aspects of wound healing and pathogenesis, 
there are a number of “core” details which should be included in all studies. These 
include details of the populations (of the people, the limb and the foot), as well as the 
interventions and the outcomes. For example, studies focussing on prevention must 
give details of the baseline risk of the development of foot disease of the population 
(at least in terms of neuropathy, arterial disease and deformity) and the specific tests 
used to assess these.  
 
Any intervention must be defined in sufficient detail to allow it to be reproduced in 
future studies, including who delivered the intervention and where it was delivered 
and in comparative studies usual care must be carefully described.  
 
In a study of ulcer healing, baseline characteristics of both the limb and the ulcer 
must be defined with a description of tests used to define them. Features of ulcers 
that are known to affect healing outcome (for example depth, area, site, whether 
single or multiple ulcers, and duration of the index ulcer) should also be defined. 
Ulcers are frequently described according to one of the many classification systems 
published [78]. Care must be taken, however, not to use these systems outside the 
purpose for which they are designed. For example the Megitt-Wagner system 
contains too little detail to establish the necessary baseline features of a population 
of ulcers [79], whilst the University of Texas system does not include neuropathy 
[80].  
 
The primary outcome of the study must be clearly stated. For example, if healing is 
the main outcome, the definition of healing, who assessed it, and whether the 
assessment was blind to the intervention needs to be stated. Often complete 
epithelialisation without drainage is used as a definition, with or without maintenance 
of healing over a stated period of time. However, some studies, particularly those of 
a surgical intervention may include wounds closed primarily surgically. If so this 
needs to be stated. Obviously, in an open label study, surgical closure may introduce 
a source of bias if the decision to surgically close a wound is done in the knowledge 
of the intervention. 
 
Of particular importance in a controlled trial is the description of usual care, which 
must include all aspects according to best practice guidance, including the 
management of infection, the provision of pressure relieving offloading devices and 
revascularisation where appropriate [81].  
 
As discussed earlier, infection is a particular problem when designing and evaluating 
clinical trials, particularly with the advent of new methods of evaluating infection and 
new novel treatments. One challenge when a study about ulcer infection is being 
designed, is to decide whether the eradication of infection or ulcer healing is the 
correct outcome measure. In most instances this should be the eradication of 
infection, as ulcer healing may be influenced by many different pathological 
processes. This in itself brings challenges, however, as deciding when infection has 
been eradicated is not straightforward. This may be defined as the disappearance of, 
or sufficient improvement in, signs and symptoms related to the infection such that it 
does not require further treatment; a clinical definition that has necessarily a degree 
of subjectivity. At present there are no microbiological tests to assess whether an 
infection has been eradicated, despite the more recent description of newer 
techniques including molecular microbiological testing [82]. 
 Finally, an objective measure of the quality of published papers is required. The 
systematic reviews performed by the International Working Group of the Diabetic 
Foot have, as with other systematic reviews, applied standard grading to the papers 
they have evaluated. Nevertheless some papers score highly, when experts in the 
field feel that inadequate clinical details have been given to understand whether an 
intervention could be useful in clinical practice above and beyond usual care. For this 
reason, a 21 point checklist has been defined which, it is hoped, will allow 
investigator’s, readers and journal editors alike to assess the quality of work in this 
area [10]. The higher the score achieved, the greater the chance that the reported 
study is free from bias and is relevant to clinical practice.  
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Legend to Figures  
 
Figure 1 
Schematic to show how the microbiology of the diabetic foot ulcer develops over 
time. The colonising bacterial species are dependent on the chronicity of the ulcer 
and the age of wound. Species number increases resulting in the evolution from a 
monomicrobial to a polymicrobial community. Adapted from reference [11]. 
 
Figure 2 
MolecuLightTM handheld fluorescence imaging device  
 
Figure 3 
PulseFlowDFTM offloading device  
 
Table 1 
Core details with should be reported for an intervention study of Diabetic Foot 
Disease (adapted from Reference 10) 
 
PAD – peripheral arterial disease ABPI – Ankle Brachial Pressure Index 
Strict anaerobes 
Enterobacteriaceae 
Pseudomonas spix 
Non-fermenting gram-neg bacilli 
.E. 
Staphylococcus aureus 
i3-haemolvticsteptococci 
PARambmk,.0,0,11 $.40319,99.901.FAWKPROM 
Time 


Table 1 
Population Intervention Outcome(s) 
Relating to the Person For each intervention sufficient 
information must be provided to 
define 
 
 Its nature (including 
source) 
 Route, frequency and 
duration of delivery 
 Delivery by whom: 
professional, non-
professional carer, self 
 Place of delivery: 
domiciliary, community 
clinic or surgery, hospital, 
specialist centre 
 
Relating to the Person 
 Age, gender, 
ethnicity 
 Diabetes type and 
duration 
 Co-morbidities 
(renal failure, heart 
failure, impaired 
vision) 
 
 Survival  
 Being ulcer-free 
and/or amputation 
free at a fixed time 
after presentation 
 Ulcer-free survival 
days 
 Adverse events 
and/or adverse 
device effects 
 Health-related 
quality of life 
 
 
Relating to the Limb Relating to the Ulcer and 
Limb 
 PAD: minimal 
assessment by 
palpation of pulses 
and ABPI  
 Neuropathy: 
minimal 
assessment by 
loss of sensation 
(eg 10g 
monofilament or 
vibration 
perception) 
 Foot deformity  
 History of previous 
foot ulceration and 
amputation 
 
Direct  
 Ulcer healing 
(defined); time to 
healing 
 Healing following 
local surgery, 
including operative 
debridement 
 Failure to heal by a 
fixed time – ulcer 
persistent 
 Amputation (with 
exact level defined) 
   
  
Possible Surrogates 
 Change in ulcer 
area by a given 
period of time 
 Change in ulcer 
appearance, 
biochemistry, 
histology or other 
laboratory measure 
of wound bed status 
 
Relating to the Ulcer 
 Number of active 
ulcers 
 Site of index ulcer 
 Duration of index 
ulcer 
 Type or 
classification of 
index ulcer (where 
appropriate) 
 Area, depth 
 Presence or 
absence of 
infection 
 
